This special series on “Follicular Lymphoma” is edited by Dr. Mark Roschewski, Clinical Director, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA and Dr. Carla Casulo, MD, Associate Professor of Medicine, Director of the Hematology/Oncology Fellowship Program, University of Rochester, Rochester, NY, USA.
Dr. Mark Roschewski is a clinician scientist and the clinical director of the Lymphoid Malignancies Branch (LYMB) of the Center for Cancer Research, National Cancer Institute (NCI). He completed his hematology-oncology fellowship at Walter Reed Army Medical Center in 2009 and joined the LYMB in 2013. He is the principal investigator on 12 active clinical trials and the associate investigator on another 5 ongoing clinical trials.
The primary goal of the NCI Lymphoma research team is to translate novel findings in the molecular biology of lymphoma into innovative therapies for patients with follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, mantle cell lymphoma, EBV-associated lymphomas, and CNS lymphomas. Recent studies from their team have demonstrated effective chemotherapy platforms that are highly effective for Burkitt lymphoma as well as subtypes of DLBCL such as primary mediastinal B-cell lymphoma. In addition, the group is focused on demonstrating the effectiveness of targeted therapies including Bruton tyrosine kinase (Btk) inhibitors in aggressive lymphomas, including those involving the central nervous system. Dr. Roschewski is an internationally recognized expert on the role of circulating tumor DNA (ctDNA) across lymphoma subtypes.
Carla Casulo, MD, Associate Professor of Medicine, is Director of the Hematology/Oncology Fellowship Program at the University of Rochester. She is also Assistant Director of Mentoring and Career Development for the Wilmot Cancer Institute. Nationally, Dr. Casulo is Chair of the American Society of Clinical Oncology Lymphoid Malignancies Education Planning Committee.
Dr. Casulo is a recognized authority in lymphoma. She has presented her work in lymphoma several times at both national and international levels, including the American Society of Hematology and American Society of Clinical Oncology. Dr. Casulo's research experience and areas of interest include relapsed follicular lymphoma, transformed (diffuse large B cell) lymphoma, newly diagnosed and relapsed Hodgkin lymphoma, and T cell lymphoma. She also has a practice focusing on young adults with lymphoma. She is board-certified in both medical oncology and hematology.
Mark Roschewski, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Carla Casulo, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
2. Pathogenesis of FL
Stefania Pittaluga, Ting Zhou, Elaine Jaffe
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
3. Genetic heterogeneity in FL
Jessica Okosun, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
4. Tumor microenvironment of FL
Maher K. Gandhi, Mater Research Institute, University of Queensland, Australia
5. Frontline management of FL
Stefano Luminari, University of Modena and Reggio Emilia, Modena, Italy; Hematology Unit, Azienda Unità Sanitaria Locale IRCCS, Arcispedale Santa Maria Nuova IRCCS, viale Risorgimento n°80 42123, Reggio Emilia, Italy
6. Treatment of early relapsed FL
Paul Barr, Thomas Rodgers
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
7. Minimal residual disease in FL
Christiana Pott, University Hospital of Schleswig-Holstein, Kiel, Germany
Marco Ladetto, Struttura Complessa di Ematologia, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
8. Novel targeted agents for FL
Franck Morschhauser, Service des Maladies du Sang, Université de Lille, Lille, France
Connie Lee Batlevi, Memorial Sloan Kettering Cancer Center, Lymphoma. Service, New York, NY, USA
9. Novel immunotherapy for FL
Stephen M. Ansell, Professor of Medicine, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Arushi Khurana, Advanced Hematology Fellow- Clinical Cell Therapy/Lymphoma, Division of Hematology, Mayo Clinic, Rochester, MN, USA
The special series “Follicular Lymphoma” was commissioned by the editorial office, Annals of Lymphoma without any sponsorship or funding. Dr. Mark Roschewski and Dr. Carla Casulo are serving as the unpaid Guest Editors for the series.